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Background: Although the relationship between body weight and blood pressure (BP) is well 
established, there is a lack of data regarding the impact of obesity on the prevalence of hypertension in 
primary care practice. The objective of this study was to assess the prevalence of hypertension and the 
diagnosis, treatment status, and control rates of hypertension in obese patients as compared to patients 
with normal weight.  
Methods: A cross-sectional point prevalence study of 45,125 unselected consecutive primary care 
attendees was conducted in a representative nationwide sample of 1912 primary care physicians in 
Germany (HYDRA).  
Results: Blood pressure levels were consistently higher in obese patients. Overall prevalence of 
hypertension (blood pressure ≥140/90 mm Hg or on antihypertensive medication) in normal weight 
patients was 34.3%, in overweight participants 60.6%, in grade 1 obesity 72.9%, in grade 2 obesity 
77.1%, and in grade 3 obesity 74.1%. The odds ratio (OR) for good BP control (<140/90 mm Hg) in 
diagnosed and treated patients was 0.8 (95% confidence interval [CI] 0.7– 0.9) in overweight patients, 
0.6 (95% CI 0.6–0.7) in grade 1, 0.5 (95% CI 0.4–0.6) in grade 2, and 0.7 (95% CI 0.5– 0.9) in grade 3 
obese patients.  
Conclusions: The increasing prevalence of hypertension in obese patients and the low control rates in 
overweight and obese patients document the challenge that hypertension control in obese patients 
imposes on the primary care physician. These results highlight the need for specific evidence-based 
guidelines for the pharmacologic management of obesity-related hypertension in primary practice.  
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Overweight and obesity are currently recognized as major public health issues in most areas 
of the world.1 For the U.S. population (National Health and Nutrition Examination Survey: 
1999–2000), Flegal et al2 reported a prevalence of 64.5% for overweight (body mass index 
[BMI] ≥25 kg/m2) and 30.5% for obesity (BMI ≥30 kg/m2). In Germany, the prevalence of 
overweight and obesity in patients presenting in primary care practice is 60% and 20%, 
respectively.3 These figures represent a substantial increase in the prevalence of excess body 
weight compared with the 1990s and is in part responsible for the current increase in health 
care expenditures.4  
 
Among overweight and obese patients, the prevalence of hypertension has been reported to be 
around 50% and to increase further with higher grades of obesity.5 On the other hand, almost 
70% of hypertensive patients have been reported to be overweight, with more than 30% being 
obese.6 Previous population-based studies suggest that the probability of insufficient blood 
pressure (BP) control in obese patients is about 50% higher than in hypertensive patients with 
normal weight.7 Yet, little is known about the prevalence and control of hypertension in 
overweight and obese primary care attendees.  
 
The Hypertension and Diabetes Risk Screening and Awareness (HYDRA) study was a cross-
sectional pointprevalence study in 45,125 primary care attendees in Germany conducted 
during September 2001.8 In this article we present data on 1) BP levels of patients according 
to age and BMI, 2) the point prevalence of hypertension in overweight and obese patients, 3) 
the proportion of recognized, treated, and subsequently controlled hypertensive patients in the 
sample population, and 4) data on the use of antihypertensive treatment in primary care.  
 
Methods  
 
Study Design  
 
The design and instruments of the HYDRA study have been presented in greater detail 
elsewhere8,9 (see also http://www.hydra-studie.de). Briefly, the HYDRA study was based on a 
two-step epidemiologic design. In step one, a nationwide sample (n = 2466) of primary care 
doctors completed a prestudy questionnaire (n = 1912; response rate 79%) to describe 
personal and structural characteristics of each practice and to assess self-perceived 
qualifications and attitudes related to recognition, diagnosis, and care of primary care patients. 
The second step consisted of a target day assessment (half day, September 18 or 20, 2001) of 
all patients attending the doctors’ offices on that day. Patients were informed by posters and 
leaflets about participation of the respective practices in the study and that they were free to 
decline participation. Informed consent was obtained from all patients. A total of 45,125 
consecutive primary care attendees, aged 16 years and older and eligible for the study, were 
enrolled irrespective of their reason for contacting the primary care physician.  
 
Instruments  
 
The prestudy questionnaire served to collect information on the participating physician’s 
profile. The patient questionnaire was used to collect data on a variety of variables including 
details on hypertension and diabetes history and treatment (if applicable). The doctor’s 
clinical appraisal included rating of the current presence of hypertension and diabetes using 
the Clinical Global Impression Scale (CGI: not present, borderline, mild/moderate, 
severe/extreme)10 and indicating co-morbidities out of 22 predefined somatic and mental 
disorders. Information on BP and biochemical data as well as the doctor’s assessment of 
diabetes or hypertension control was also collected. In addition systolic and diastolic BP was 
measured by the doctor by sphygmonanometry or automated, validated devices. It should be 
noted that this was a naturalistic study in routine care with no monitors carrying out quality 
assurance, and thus it is not feasible to quantify to what degree doctors complied with the 
rules. In particular, it is not possible to indicate whether doctors based their hypertension 
indication on one or more measurements.  
 
Diagnostic Conventions  
 
As in previous studies,11 hypertension was defined as measured BP equal to or greater than 
140/90 mm Hg or receiving antihypertensive therapy. Detection levels were based on the 
doctor’s clinical diagnoses as reported and coded on the clinical appraisal form. The BMI was 
calculated from self-reported weight and height information taken from the patients 
questionnaire (body weight in kilograms/height in meters squared) and classified according to 
international conventions: overweight (25–29.9 kg/ m2), obesity (≥30 kg/m2), obesity grade 1 
(30–34.9 kg/m2), grade 2 (35–39.9 kg/m2), and grade 3 (≥40 kg/m2).6  
 
Statistical Analyses  
 
From the total HYDRA sample of 45,125 patients, 6252 were excluded due to missing values 
for weight and height (2185), underweight (BMI <18,5 kg/m2) (841), missing CGI ratings for 
diabetes (1467), or missing BP readings (1759). Thus, these point-prevalence estimates are 
based on a sample of 38,873 primary care attendees (Table 1). Cross-tables, frequency 
distributions, and descriptive statistics were used to compare the distributions of variables 
among all categories. Differences in binary outcomes like the presence of hypertension were 
quantified with odds ratios (ORs) from logistic regressions,12 while adjusting for age group, 
sex, and sex times age group, and by calculating robust confidence intervals for observations 
clustered within primary care settings.13 All analyses were conducted using the Stata 8 
software package (StataCorp LP, College Station, TX).  
 
Results  
 
Mean BP Readings  
 
Blood pressure levels by BMI and age group are plotted in Fig. 1. In the overall sample 
(treated and untreated hypertensive patients), systolic BP consistently increased with BMI and 
age. The same was true for all untreated patients except for the youngest age group, where BP 
levels in grade 3 obesity were lower than in grade 2 patients. In treated patients, systolic BP 
likewise increased with increasing age and BMI, although this relationship was attenuated by 
treatment. Similar trends were seen for diastolic BP and in both sexes (data not shown).  
 
Prevalence of Hypertension in Overweight and Obese Patients  
 
Table 1 shows the overall prevalence of hypertension by age groups, sex, and BMI. Overall 
prevalence of hypertension in normal weight patients was 34.3%, in overweight 60.6%, in 
grade 1 obesity 72.9%, in grade 2 obesity 77.1%, and in grade 3 obesity 74.1%. The 
prevalence of hypertension increased with higher BMI in all age groups, but this relationship 
was stronger in the younger age groups (Fig. 2). As with BP levels in the youngest age group, 
the prevalence of hypertension in the grade 3 obese patients was lower (37%) than in the 
grade 2 obese (51%). The same BP trends were seen in both sexes.  
 
Using a more stringent BP cutoff of 130/80 mm Hg, as recommended for high-risk patients,14 
prevalence of hypertension increased from 68% in patients with normal body weight (for 
whom the lower targets would not apply), to 87% for overweight (OR 2.1, 95% confidence 
interval [CI] 2.0–2.2), 92% for grade 1 obese (OR 3.9, 95% CI 3.6–4.3), 95.0% for grade 2 
obese (OR 6.0, 95% CI 5.2–7.0), and 92% for grade 3 obese patients (OR 5.5, 95% CI 4.4–
6.9).  
 
Hypertension Diagnosis, Treatment, and Control  
 
Fig. 3 shows the proportion of all primary care attendees who were hypertensive, were 
diagnosed as having hypertension by the physician, were treated, and were controlled (BP 
<140/<90 mm Hg). Although prevalence of hypertension increased with BMI class (falling 
off slightly in men with grade 3 obesity), the relative rates of detection and treatment likewise 
increased. However, ORs for good control were 0.8 (95% CI 0.7–0.9) in overweight patients 
compared with normal weight patients, OR 0.6 (95% CI 0.6–0.7) in grade 1, OR 0.5 (95% CI 
0.4–0.6) in grade 2, and OR 0.7 (95% CI 0.5–0.9) in grade 3 obese patients.  
 
Antihypertensive Medication  
 
Fig. 4 illustrates the use of different drug classes for each BMI group among recognized 
hypertensive patients. There was a significant increase in the use of angiotensin-converting 
enzyme inhibitors and diuretics with increasing BMI class (OR 1.9, 95% CI 1.5–2.4 for the 
use of angiotensin-converting enzyme inhibitors and OR 2.8, 95% CI 2.2–3.5 for diuretics in 
grade 3 obesity). The use of other drug classes was not related to BMI class.  
 
The use of drug combinations in patients with treated hypertension is illustrated in Fig. 5. 
While the frequency of the use of only 1 drug (normal weight 51.1%) decreased with 
increasing weight (35.1% for grade 3 obesity), the number of patients taking 2, 3, or ≥ 4 
antihypertensive drugs increased substantially with increasing weight. The OR for the use of 4 
drugs in grade 3 obesity was 5.3 (95% CI 3.1–8.9), for 3 drugs it was 3.2 (95% CI 2.1–4.9), 
and for 2 drugs it was 2.3 (95% CI 1.6–3.3) versus normal weight.  
 
The use of β-blockers predicted good BP control (<140/90 mm Hg) compared with the use of 
diuretics. This was true for patients with normal weight (OR 1.4, 95% CI 1.1–1.8) as well as 
for patients who are overweight (OR 1.3, 95% CI 1.1–1.7) or obese (OR 1.3, 95% CI 1.1–
1.5). In contrast, neither the use of calcium channel blockers, angiotensin-converting enzyme 
inhibitors, AT1- receptor blockers, α-blockers, nor the number of drugs used were predictors 
of BP control.  
 
Discussion  
 
This study, based on data derived from more than 45,125 primary care attendees, not only 
documents the high prevalence of hypertension in primary care practice, but also highlights 
the remarkable increase in the prevalence of hypertension associated with overweight and 
obesity observed in this setting. Thus, the already high prevalence of ~35% in the normal 
weight group more than doubled with grade 3 obesity. Importantly, this relationship between 
increased body weight and hypertension prevalence was most apparent among the younger 
age groups, with an almost fivefold increase in the 16- to 29-year olds and a nearly fourfold 
increase in the 30- to 44-year age group. In contrast, in the elderly (>65 years), the impact of 
BMI on hypertension prevalence and BP was rather modest (~10% increase). Overall, our 
data demonstrate that apart from age, BMI is a very important determinant of BP levels, 
hypertension prevalence, and BP control in primary practice.  
 
Our observation on the importance of BMI as a determinant of hypertension in primary 
practice is consistent with the well-known positive relationship between increased body 
weight and higher BP.15,16 Similarly, the Third National Health and Nutrition Examination 
Survey (NHANES III) reported an increasing rate of hypertension with increasing BMI 
class.5 Thus, in NHANES, although the prevalence of hypertension was 23.5% for men with 
normal weight (23.3% for women), it was 34.2% (38.8%) for overweight, 49.0% (48.0%) for 
class 1 obesity, 65.5% (54.5%) for class 2 obesity, and 64.5% (63.2%) for class 3 obesity. 
Although the steep relationship between BMI and hypertension observed in NHANES is 
compatible with the observations in our study, the overall prevalence of hypertension at each 
level of BMI was substantially higher in the HYDRA study. These higher prevalence rates of 
hypertension are perhaps in line with the recent report by Wolf-Maier and colleagues,17 who 
described substantial differences in the prevalence of hypertension between the U.S. and 
German populations. Higher prevalence rates in our study probably also reflect the fact that 
our study was restricted to primary care attendees rather than the general population.  
 
In our study, the strong relationship between increase in BMI and both systolic and diastolic 
BP was apparent both in treated and, albeit at substantially lower BP levels, in untreated 
patients. In contrast, although treatment failed to normalize BP in the majority of hypertensive 
patients, it apparently sufficed to markedly decrease the overall BP variance such that the 
relationship between BMI and BP levels was virtually abolished. Nevertheless, increased BMI 
was a substantial risk factor for poor BP control, a finding that is well in line with previous 
observations.7 Furthermore, the number of patients on more than one antihypertensive drug 
increased from 49% in the normal weight group to 65% in grade 3 obese patients.  
 
Interestingly, although overall control rates were rather low in all BMI groups, the use of β-
blockers was a significant predictor of good control. The fact that this was also true for obese 
patients may reflect the previous finding that β-blockade is more effective in lowering BP in 
obese than in lean patients.18 On the other hand, there have been reservations on the use of 
these agents in obese patients based on their propensity to cause weight gain19 and to increase 
the incidence of diabetes.20 In fact, whether or not β-blockers should be first-line treatment for 
young patients with uncomplicated obesity-related hypertension remains a matter of debate,21 
which should be addressed by current guidelines.14,22 In the HYDRA study, clear preference 
of antihypertensive drug classes in obese patients was only apparent for diuretics and 
angiotensin-converting enzyme inhibitors, with their use progressively increasing with higher 
BMI classes. Whether or not the choice of these agents is a reflection of their better efficacy 
or is dictated by better tolerability or specific indications for obesity-related co-morbidities 
remains unclear.  
 
Poor control of obesity hypertension may be related to its complex pathophysiologic effects 
on renal function and morphology. Obesity increases renal sodium reabsorption and impairs 
pressure natriuresis by activation of the reninangiotensin and sympathetic nervous systems 
and by altered intrarenal physical forces.23 Chronic obesity also causes marked structural 
changes in the kidneys that eventually lead to a loss of nephron function, further increasing 
arterial pressure. Recent evidence suggests that some of these alterations may be attributable 
to adipocyte-derived factors (termed adipokines) that can directly affect metabolism, 
neurohumoral vascular control, and renal function.24 It is, therefore, perhaps not surprising 
that in this survey, diuretics and blockers of the renin-angiotensin system were more likely to 
be used in obese patients than other drug classes.25  
 
There are several limitations to our study. First, BMI was calculated based on the data 
provided in the patient questionnaire. Self-reported weight and height are nevertheless highly 
correlated with measured weight and height, with a small systematic error generally resulting 
in an overestimation of height and an underestimation of weight, resulting in an 
underestimation of BMI.26 Therefore, the true prevalence of overweight and obesity may be 
even higher than reported in our study. Also, BP readings were obtained only once on the 
study day after 3 min of rest. Although this may not suffice to fully characterize BP levels in a 
given patient, it has been shown that one time BP testing is feasible and gives reliable 
estimates in large patient cohorts.27 Furthermore, we were able to assess the validity of the 
one time measure by asking doctors to provide a second measure from the chart (median time, 
2 months before the study). These measures were available in two-thirds of the reported cases 
and the mean BP of these measurements was almost identical to the data reported here. 
Finally, BP readings before the diagnosis of hypertension were not evaluated. Thus, the 
magnitude of BP reduction, an important factor in evaluating the success of therapy, could not 
be determined. A patient whose BP was lowered from 210/110 mm Hg to 150/90 mm Hg was 
classified identically as a patient whose BP was reduced only from 150/95 mm Hg to 142/92 
mm Hg, although the morbidity and mortality risk of the former patient would have been 
lowered to a considerable extent.28 Thus, evaluating only whether a given patient was below 
the recommended threshold, most likely underestimates the benefit of BP therapy for a given 
patient.  
 
In conclusion, our study not only documents the high prevalence of obesity and hypertension 
in primary practice, but also emphasizes the steep relationship between these two entities in 
younger patients. The striking lack of control was even more pronounced in the obese groups 
with obesity being a significant predictor of poor control, despite the greater use of 
combination therapy. Preferential use of drugs in obese patients was only apparent for 
diuretics and angiotensin-converting enzyme inhibitors, although the use of β-blockers was a 
significant predictor of good BP control in all groups. Whether or not these findings reflect 
better efficacy of these drugs in obese patients or their use is dictated by other factors remains 
to be studied.  
 
Perspectives  
 
Despite the well-recognized relationship between increased body weight and BP, there is a 
remarkable paucity of data on the prevalence of obesity and its relationship to hypertension in 
medical practice. Our data emphasize not only the magnitude of this relationship but also 
show that obesity is a predictor of poor control. The results of our study also highlight the 
need for evidence-based guidelines on the pharmacologic management of obesity-related 
hypertension.  
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